Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modified recombinant human erythropoietin with potentially reduced immunogenicity.

Scientific reports - 15 Jan 2021

Susantad Thanutsorn, Fuangthong Mayuree, Tharakaraman Kannan, Tit-Oon Phanthakarn, Ruchirawat Mathuros, Sasisekharan Ram

Abstract excerpt

Recombinant human erythropoietin (rHuEPO) is a biopharmaceutical drug given to patients who have a low hemoglobin related to chronic kidney disease, cancer or anemia. However, some patients repeatedly receiving rHuEPO develop anti-rHuEPO neutralizing antibodies leading to the development of pure red cell aplasia (PRCA). The immunogenic antibody response activated by rHuEPO is believed to be triggered by T-cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Antibody Formation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Culture Techniques

Share to Erythropoietin

Share to Major Histocompatibility Complex

Share to Protein Engineering

Share to Recombinant Proteins

Share to Renal Dialysis

Source

Open in PubMed Open full text

Identifiers

PMID: 33452310
DOI: 10.1038/s41598-020-80402-1
PMCID: PMC7810742

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modified recombinant human erythropoietin with potentially reduced immunogenicity.PMID 33452310Read ↗

Development of a strategy and computational application to select candidate protein analogues with reduced HLA binding and immunogenicity.Semantic proximity Read ↗

A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeuticsSemantic proximity Read ↗

Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo.Semantic proximity Read ↗

Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools.Semantic proximity Read ↗

Protein deimmunization via structure‐based design enables efficient epitope deletion at high mutational loadsSemantic proximity Read ↗

Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia.Semantic proximity Read ↗

Optimization of therapeutic proteins to delete T-cell epitopes while maintaining beneficial residue interactions.Semantic proximity Read ↗

Structure-Guided Deimmunization of Therapeutic ProteinsSemantic proximity Read ↗

Immunogenicity screening in protein drug developmentSemantic proximity Read ↗

In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancementsSemantic proximity Read ↗

Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII.Semantic proximity Read ↗

Mapping of the Active Site of Recombinant Human ErythropoietinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.